Successful treatment of recalcitrant candidal intertrigo with Dr Michaels® (Fungatinex®) product family
Jazyk angličtina Země Itálie Médium print
Typ dokumentu klinické zkoušky, časopisecké články
PubMed
27498664
PII: 14
Knihovny.cz E-zdroje
- MeSH
- aplikace kožní MeSH
- diabetes mellitus 2. typu komplikace MeSH
- fytoterapie * MeSH
- intertrigo komplikace farmakoterapie patologie MeSH
- kandidóza kožní komplikace farmakoterapie patologie MeSH
- komplementární terapie metody MeSH
- kůže účinky léků patologie MeSH
- lidé MeSH
- masti aplikace a dávkování terapeutické užití MeSH
- obezita komplikace MeSH
- péče o kůži metody MeSH
- senioři MeSH
- Check Tag
- lidé MeSH
- mužské pohlaví MeSH
- senioři MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- klinické zkoušky MeSH
- Názvy látek
- masti MeSH
Candidal intertrigo is an infection of the skin caused by Candida albicans that typically occurs in opposing cutaneous or muco-cutaneous surfaces. Because Candidiasis requires a damaged and moist environment for infection, it typically occurs in areas of friction such as the skin folds of the body. Candidal intertrigo is often difficult to treat and results are often unsatisfactory. In addition, there is a lack of evidence-based literature supporting prevention and treatments for candidal intertrigo. The aim of the study was to evaluate the efficacy of Dr Michaels® (also branded as Fungatinex®) products in the treatment of fungal intertrigo, in 20 women and 2 men with a mean age of 72. Five patients (3 female and 2 male) had type 2 diabetes and 16 (14 female and 2 male) were obese. The patients were treated with Dr Michaels® (Fungatinex®) moisturising bar, topical ointment (twice daily application) and oral herbal formulation, PSC 200 two tablets twice daily with food. After 2 weeks of treatment, the lesions had mostly resolved in all patients with only slight erythema evident. After six weeks of treatment using the moisturising bar, topical ointment and oral herbal formulations from the Dr Michaels® (Fungatinex®) product family, the lesions had totally resolved in 18 patients, while 4 patients had to continue the therapeutic protocol for another 2 weeks. Our results demonstrate that the Dr Michaels® (Fungatinex®) complementary product family is efficacious in the treatment of recalcitrant candidal intertrigo. Furthermore, this study highlights that the Dr Michaels® (Fungatinex®) product family is fast-acting and well tolerated with no serious adverse events reported. These data have important implications for resistant cases of candidal intertrigo where traditional therapies have failed.
Chair of Dermatology University of Rome G Marconi Rome Italy
Department of Nuclear Physics Sub nuclear and Radiation Guglielmo Marconi University Rome Italy
Dermatological Department University of Pisa Pisa Italy
PRO SANUM Ltd Sanatorium of Prof Novotný Štěpánská Prague 1 Czech Republic
Psoriasis and Skin Clinic Melbourne Australia
University B 1 S Group of Institutions Punjab Technical University Punjab India